Phase 2 Recurrent Glioblastoma Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 2
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
BioNTech SE75 enrolled6 locationsNCT07297212
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 2
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Recurrent Glioblastoma
Duke University80 enrolled4 locationsNCT06069726
Recruiting
Phase 2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683
Recruiting
Phase 2
Sacituzumab Govitecan in Recurrent Glioblastoma
Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio32 enrolled3 locationsNCT04559230
Recruiting
Phase 2
Surgical Pembro +/- Olaparib w TMZ for rGBM
GlioblastomaRecurrent Glioblastoma
L. Nicolas Gonzalez Castro, MD, PhD78 enrolled4 locationsNCT05463848
Recruiting
Phase 2
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Metastatic CancerLeptomeningeal MetastasisBrain Cancer+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT06058988
Recruiting
Phase 2
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 2
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
Recurrent Glioblastoma
University of Florida20 enrolled1 locationNCT06558214
Recruiting
Phase 1Phase 2
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Not Yet Recruiting
Phase 2
A study in participants with glioblastoma that has progressed after standard of care therapy, looking at the safety and effect of treatment with the experimental drug E-EDV-Dox/GC or EnGeneIC Dream Vectors (EDVs) packaged with the chemotherapy (Doxorubicin) given simultaneously with non-targeted EDVs carrying an immune enhancer called EDV-GC. (EDV-GBM Trial)
Recurrent Glioblastoma
EnGeneIC Pty Ltd30 enrolled2 locationsACTRN12625000779471
Recruiting
Phase 2
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled1 locationNCT06598787
Recruiting
Phase 1Phase 2
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
GlioblastomaRecurrent Glioblastoma
Emory University24 enrolled1 locationNCT04590664
Recruiting
Phase 2
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Academic and Community Cancer Research United134 enrolled3 locationsNCT06160206
Recruiting
Phase 2
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University20 enrolled1 locationNCT06220552
Terminated
Phase 2
A Phase 1/2 study to determine the effect of Doxorubicin loaded EnGeneIC Delivery Vehicles on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM)
Recurrent Glioblastoma Multiforme
EnGeneIC Ltd46 enrolled1 locationACTRN12613000297729
Terminated
Phase 2
AMP: Phase I/II study of AMG 102 and panitumumab in recurrent Glioblastoma Multiforme (GBM)
Recurrent Glioblastoma Multiforme (GBM)
University of Sydney42 enrolled1 locationACTRN12610000092099